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Abstract
The use of glucocorticoids (GC) in the medium and long term, causes several 
considerable side effects, being one of the main ones the reduction of bone mineral 
density (BMD). Prolonged corticosteroid therapy reduces BMD by up to 20% in tra-
becular bone and approximately 2–3% in cortical bone in the first year of use. This 
loss rate declines and stabilizes at approximately 2% in subsequent years. Therefore, 
there is a considerable increase in the incidence of pathological fractures, whether 
clinically symptomatic or asymptomatic (detected as a radiological finding), which 
varies between 30 and 50% of patients who use GC for more than three months. 
In view of the above, it is essential to prevent fractures and treat osteoporosis in 
patients using glucocorticoids for long periods (in particular, greater than or equal 
to 3 months), which may or may not be associated with clinical risk factors or previ-
ous fractures. The guidelines for the treatment and prevention of this comorbidity 
are well established for postmenopausal women and men over 50 years of age. 
However, for patients below this range, studies are still lacking.
Keywords: Osteoporosis, Glucocorticoids, Bone Fractures, Primary Prevention, 
Drug Therapy
1. Introduction
Glucocorticoids (GCs) are common medications in daily medical practice. 
About 0.5% and 1% of the populations in the United Kingdom and the United States 
use this drug class on an ongoing basis, respectively [1–17]. The use in the medium 
and long term, causes several considerable side effects, being one of the main ones 
the reduction of bone mineral density (BMD). Prolonged corticosteroid therapy 
reduces BMD by up to 20% in trabecular bone and approximately 2–3% in cortical 
bone in the first year of use. This loss rate declines and stabilizes at approximately 
2% in subsequent years [1–9, 11–15, 17, 18].
Therefore, there is a considerable increase in the incidence of pathological 
fractures, whether clinically symptomatic or asymptomatic (detected as a radiologi-
cal finding), which varies between 30 and 50% of patients who use GC for more 
than three months [1–31]. The fracture can be said to be pathological when it occurs 
with as little stress as possible and falls from one’s own height, which would not 
cause fractures in healthy bones. The risk of fracture for a given BMD is greater in 
GC-induced osteoporosis (GIO) than senile or postmenopausal. In these last two, 
the stimulus for bone matrix synthesis is not affected [1–6, 11–15, 17, 26].
In view of the above, it is essential to prevent fractures and treat osteoporosis 
in patients using glucocorticoids for long periods (in particular, greater than or 
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equal to 3 months), which may or may not be associated with clinical risk factors or 
previous fractures [1–31].
2. Pathogenesis
The side effects of corticosteroids on the bone system can occur indirectly or 
directly. Indirectly, corticosteroids increase urinary calcium excretion and vitamin 
D metabolism, reduce intestinal absorption of vitamin D, influence parathyroid 
hormone (PTH) secretion, reduce GH and IGF-1 levels and cause hypogonado-
tropic hypogonadism (Figure 1). Directly, they act on osteoclasts by increasing 
the ligand of the nuclear factor activating receptor Kappa-B (RANK) and decreas-
ing osteoprotegerin (OPG); on osteocytes causing apoptosis; and on osteoblasts 
inhibiting bone formation (Figure 1). The final effect is to reduce bone formation 
and stimulate its resorption, causing early bone loss and low bone mass in the long 
run. Trabecular bone is more prone to deleterious effects than cortical bone, with 
a more pronounced effect in the first year, especially in the first 6 months, and 
decays at a steady rate over the next few years. With chronic use, the stimulus to 
bone resorption is reduced and the suppression of bone formation becomes the 
dominant effect [2–7, 11–15, 17, 18, 26].
2.1 Increase in bone resorption
As in other tissues, glucocorticoids exert their effect from the genetic expres-
sion of type 2 glucocorticoid cytoplasmic receptors. In adult bone, such receptors 
are found in pre-osteoblastic/stromal cells, the osteoblasts, which produce the 
bone matrix, but not in osteoclasts. GCs stimulate the proliferation of these cells 
by inhibiting the synthesis of osteoprotegerin, an inhibitor of the differentiation 
of hematopoietic cells of the macrophage lineage into osteoclasts and stimulating 
the production of RANK, which is necessary for osteoclastogenesis. High serum 
levels of GCs stimulate the synthesis of RANK ligands (RANKL), sustaining dif-
ferentiation in osteoclasts and, consequently, bone matrix reabsorption (Figure 2). 
In addition, they reduce the production of androgens and estrogens, suppressing 
Figure 1. 





gonadotropin secretion by the adenohypophysis and consequent stimulus for bone 
resorption. GCs reduce intestinal calcium absorption, promoting antagonism to 
the action of vitamin D and by reducing the expression of calcium channels in the 
duodenum. They increase the excretion of calcium and reduce renal reabsorption. 
Both actions promote increased parathyroid hormone secretion and, consequently, 
bone resorption [2, 3, 5, 11–15, 17, 26].
2.2 Inhibition of bone formation
In GCs chronic use, the predominant effect will be the reduction of bone 
formation. This is generated by the direct reduction of osteoblastic prolifera-
tion and differentiation of precursors and stimulation of apoptosis of mature 
osteoblasts and osteocytes, increasing the risk of osteonecrosis. It changes the 
dynamics in the release of PTH, with reduced tonic secretion and increased 
pulses, inhibiting the anabolic action of this hormone. It also reduces the pro-
duction of insulin-like growth factor (IGF-1) and testosterone. The reduction in 
bone formation is associated with a reduction in the rate of mineral apposition 
and can be documented by the low levels (serum and urinary) of biochemical 
markers of bone formation [2, 3, 5, 11–15, 17, 26].
3. Epidemiology and risk factors
The chronic use of GCs increases the risk of fractures, particularly in trabecu-
lar bones (in particular, vertebrae) and in the early phase of treatment, when the 
rate of bone loss is greatest. Its effect is greater in advancing age, dose and dura-
tion of treatment [2, 11–13, 17, 27]. A dose of 2.5–7.5 mg per day of prednisone (or 
equivalent), in less than 30 days, is enough to increase the risk of fractures. Below 
are patients with clinical risk factors for osteoporosis and pathological fractures 
[2, 11–13, 17, 27, 28]:
Major risk factors:
• History of previous fracture in adulthood;
• History of fracture in first-degree relatives;
Figure 2. 
Direct mechanisms of action of cortisol via the RANK/RANKL/OPG pathway (Richards et al., 2012, 
adapted) [26].
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• Current smoking;
• Low weight (BMI less than 18Kg/m2);
• Concomitant diseases requiring chronic use of glucocorticoids (e.g., autoim-
mune inflammatory and pulmonary diseases, adrenal insufficiency).
Minor risk factors:
• Advanced age;
• Deficit of estrogen (e.g., menopause before the age of 45);
• Low calcium intake during life;
• Sedentary lifestyle;
• Alcoholism (3 or more doses of alcohol per day);
• Dementia (risk of falls).
4. Clinical findings
Generally, there are no clinical manifestations, except in the presence of fractures, 
in which there may be a stature reduction or local pain that worsens movement. The 
clinic will depend on the fractures involved. It is not uncommon to find asymptom-
atic fractures in imaging exams performed for other reasons. Patients with vertebral 
fracture (the main type involved), when symptomatic, present with low back pain 
that worsens when they get up, sit or cough. There is usually no history of associated 
trauma [7, 11–15].
5. Determining bone mineral density
The main standardized method for calculating bone mineral density is bone 
densitometry by dual-energy X-ray absorptiometry; (DXA). In addition, DXA can 
provide some additional information such as the presence of fractures through the 
VFA (“Vertebral Fracture Assessment”) or changes in bone quality, through the 
TBS (“Trabecular Bone Score”) [11–13, 15, 16, 21–25, 27, 29–31]. The World Health 
Organization (WHO) chooses this method, associated with the analysis of the 
results with the scores for the definition of Osteoporosis and Osteopenia. These 
scores are based on several studies with postmenopausal and white female patients 
(Table 1). There are two scores used [2, 4, 11–13, 15, 16, 21–25, 29, 30]:
• T-score: for postmenopausal women or men over 50 years old. Osteopenia is 
defined with a T-score between −1.1 and − 2.4 and osteoporosis less than or 
equal to −2.5.
• Z-score: for pre-menopausal women and men under 50 years old. If the score 
is less than or equal to −2.0, we should use the term “low bone mineral density 




NOTE: The terms osteopenia and osteoporosis should be avoided in children, 
using the term “low bone mineral density for age and sex”, if the Z-score is less than 
or equal to −2.0. The diagnosis of “osteoporosis” in children requires, associated 
with bone densitometry, at least 1 episode due to pathological fracture in a long 
bone in the lower limb or vertebra or 2 episodes in long bones in the upper limbs. 
Secondary causes of reduced bone mineral mass should be investigated in patients 
with a Z-score below −2.0. For this, use complementary exams such as 24-hour 
calciuria, which is usually increased in GIO [2, 11, 12, 15, 21–23, 27, 28].
Advanced bone mass measurement methods, including high resolution com-
puted microtomography (micro-CT) and magnetic resonance imaging (micro-
MR) allow for three-dimensional, non-invasive assessment of bone architecture. 
Although these methods help in the diagnosis of OIG, they are not used in medical 
practice, and their use is reserved only in clinical research [11, 12, 15, 23, 27, 28].
6. Approach to the patient on prolonged glucocorticoid therapy
Every adult patient using a dose greater than or equal to 2.5-5 mg per day for 
3 months or more will benefit from osteoporosis prevention intervention. In 
children, candidates will be those who are using a dose greater than or equal to 
0.16 mg/Kg/day or who have been submitted to at least 4 courses of pulses of gluco-
corticoids. Non-pharmacological measures and vitamin and calcium supplementa-
tion will be performed for all patients. For pharmacological therapy, there will be 
specific criteria [3, 5, 6, 11, 12, 15, 27, 28].
6.1 Candidates for pharmacological therapy
Determining factors, to high-risk fracture patients, who will benefit most from 
pharmacological therapy itself, are [3, 5, 6, 9–12, 15, 27, 28]:
• Patients with a previous diagnosis of osteoporosis (history of pathological 
fracture or T-score equal to or less than −2.5, calculated by bone densitometry).
• For patients without established osteoporosis, use tools that calculate the risk 
of pathological fracture, such as the fracture risk assessment tool (FRAX®).
Criteria Definitions
T-score Number of SD above or below peak bone mass (“young normal”) according 
to race or ethnicity
Z-score Number of SD above or below age-matched bone mass according to gender 
and race or ethnicity
Normal BMD T-score ≥ −1,0
Low bone mass 
(osteopenia)
BMD T-score between −1,1 and − 2,4
Osteoporosis BMD T-score ≤ −2,5
Severe osteoporosis BMD T-score ≤ −2,5 with one or more fragility fractures
BMD: bone mineral density; DXA: dual-energy X-ray absorptiometry; SD: standard-deviation; WHO: World 
Health Organization.
Table 1. 
WHO definition of osteoporosis for postmenopausal women based on DXA measurements.
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6.2 FRAX®
FRAX® is a tool, created in 2008 by Dr. John Kanis of the University of 
Sheffield, that estimates the 10-year probability of hip fracture or combined major 
osteoporotic fractures (hip, vertebrae, shoulder or wrist) in untreated patients 
among 40–90 years, using bone mineral density of the femoral neck and associated 
clinical risk factors, including use of GCs [4, 8–13, 15, 16, 18, 21–25, 27, 29–31]. The 
percentage calculated by the tool must be corrected by the dose of GCs used. For 
example, for a patient using a prednisolone dose greater than 7.5 mg/day (or equiva-
lent), the calculated risk of 15% for major osteoporotic fractures and 20% for hip 
fractures should be added to the calculated risk [2, 11–13, 15, 27].
In North America, the corrected calculations follow as possible results  
[2, 4, 8–13, 15, 16, 18, 21–25, 27, 29–31]:
• High risk: 10-year probability of a major combined osteoporotic or hip fracture 
greater than or equal to 20% and 3%, respectively.
• Moderate risk: 10-year probability of major combined osteoporotic or hip 
fracture between 10 and 19% and 1–3%, respectively.
• Low risk: 10-year probability of major combined osteoporotic or hip fracture 
less than 10% and 1%, respectively.
Patients can be at high risk for fractures even with FRAX® without being at high 
risk. For example, a patient with clinical factors for fractures and low lumbar bone 
mineral density, but with normal femoral neck bone density. This situation can 
occur especially in patients using GCs [11–13, 15, 27]. Trabecular bone score (TBS) 
could be used to access the bone quality and adjust risk fracture given by FRAX® 
[8–13, 15, 16, 18, 21–25, 29, 30]. Therefore, the treatment must be individualized 
between the patient and the attending physician [2, 5, 6, 11–13, 15, 27, 28].
6.3 For postmenopausal women and men over 50
Consider pharmacological therapy in patients with moderate to high risk  
[2, 5, 6, 11–13, 15, 27, 28]:
• Above patients with previous pathological fracture or bone densitometry with 
a T-score less than or equal to - 2.5 standard-deviations (SD), using any dose of 
glucocorticoid (prevention or treatment).
• High-risk men and postmenopausal women with a T-score between −1.1 and 
2.4 SD using any dose of glucocorticoid. Perform the FRAX® calculation and 
assess high risk if total risk of osteoporotic and hip fracture greater than or 
equal to 20% and 3%, respectively.
• For postmenopausal women and men over 50 years old and with FRAX® with 
values lower than those reported above, we recommend starting pharmaco-
logical therapy if a dose of prednisone greater than or equal to 7.5 mg per day 
(or equivalent), for more than 3 months.
6.4 For pre-menopausal women and men under 50
The decision to start drug therapy must be individualized. In these individuals, 




in other populations using GCs. The FRAX® tool was not developed for this group 
of patients. It is suggested to evaluate treatment and, in case of hypogonadism, to 
associate hormone replacement therapy (to evaluate if there are any contraindica-
tions) [2, 11–13, 15, 27, 28].
Women should use highly effective contraceptives, given the lack of studies 
on the effects of drugs used in the treatment of GIO, especially bisphosphonates, 
on the fetus. Consider pharmacological treatment for the following groups of 
patients [2, 11–13, 15, 27, 28]:
• For pre-menopausal women and past pathological fractures;
• For pre-menopausal women without a past pathological fracture, but with 
accelerated bone loss (greater than or equal to 4% per year) or a Z-score less 
than −3.0, while receiving GCs with a prednisone dose greater than or equal to 
7.5 mg per day (or equivalent) for 3 months or more).
• For men under 50 and with a past pathological fracture;
• Man under 50 years old with no past pathological fracture, but with acceler-
ated bone loss (greater than or equal to 4% per year) or Z-score less than −3.0, 
while receiving GCs at a dose of prednisone greater than or equal to 7.5 mg per 
day (or equivalent) for 3 months or more;
• Men under 50 years old and pre-menopausal women and ingested more than 
30 mg per day of prednisone (or equivalent) for more than 1 month.
7. Prevention and treatment
7.1 Non-pharmacological measures
The measures should be performed on all patients for whom treatment and 
prevention are indicated. Despite lacking studies on the reduction of fracture 
incidence, the American College of Rheumatology (ACR) defends the following  
[2, 5, 6, 10–13, 15, 27, 28]:
• Dose of glucocorticoid should be the lowest possible for resolution of the target 
disease;
• When possible, topical therapy (ointments, inhaled corticosteroids) will 
be preferable if compared with oral and intravenous corticosteroids (these 
have systemic effects), according to the associated pathology to be  
treated;
• Performing physical exercises with moderate muscle impact to reduce 
bone loss;
• Cessation or avoiding smoking;
• Limit alcohol intake to 3 doses a day or stop using it;
• Measures to prevent falls (especially in patients with dementia and the 
elderly).
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7.2 Calcium and vitamin D supplementation
GCs induce a negative balance by reducing intestinal calcium absorption and 
increasing their urinary excretion. Thus, for all patients using corticosteroids for 
3 months or more, it is recommended to keep calcium intake between 600 and 
1200 mg of elemental calcium per day and vitamin D between 400 and 800 IU/ day 
[2, 5, 6, 10–13, 15, 27, 28]. These doses can be in the diet or supplementation. Maintain 
serum vitamin D levels greater than or equal to 20 ng/dL. Another measure would 
be the low sodium diet, aiming to reduce calciuria and, if necessary, to introduce 
thiazide diuretics [2, 11, 12, 15, 27, 28].
Such measures, despite reducing the rate of bone density loss, are not sufficient 
to prevent bone mass loss and pathological fractures in patients using high doses 
of GCs. In some cases, pharmacological therapy is necessary, with the use of active 
metabolites of vitamin D (such as calcitriol and alpha-calcidiol), which have greater 
action. Calcitriol (0.25 mcg per day) associated with calcium has a greater protec-
tive effect against vertebral fractures than the isolated use of calcium in patients 
using GCs. However, active vitamin D metabolites are at increased risk of hypercal-
cemia and hypercalciuria. In addition, some studies demonstrate less effectiveness 
of these when compared to medications already on the market, such as bisphospho-
nates, for example [2, 10–12, 15, 27, 28].
7.3 Hormonal replacement in hypogonadism
In patients with hypogonadism, GCs can reduce the release of gonadotropins and, 
consequently, estrogens and androgens. In this group, as long as there are no contra-
indications, hormone replacement is indicated. For women in menopause, who are 
hypogonadic and using GC, replacement of estrogen/progestin form is indicated. 
Oral contraceptives can be started until treatment with corticosteroids ceases. If con-
traindications to oral contraceptives (migraine with aura, important side effects), 
standard doses of estradiol and progesterone can be used. In a patient with normal 
ovarian function, hormone replacement is not indicated [11–13, 15, 27, 28].
7.4 Pharmacological treatment - therapy of choice
In men and postmenopausal women, bisphosphonates are the class of choice. 
Alendronate and risendronate are preferable because they have larger studies and better 
efficacy in them. For patients with drug intolerance, difficulty with dosage or adher-
ence, intravenous zoledronic acid (zoledronate) is preferable [2, 5, 6, 9–13, 15, 27, 28].
Parathormone or analogues such as teriparatide are indicated for patients with 
severe osteoporosis: T-score less than −3.5 SD without fractures or below −2.5 SD 
and history of pathological fracture preferable [2, 5, 6, 9–13, 15, 27, 28].
Teriparatide is an option if there is an intolerance to bisphosphonates or if there 
is a fracture after 1 year of treatment with 1st line drugs. Denosumab is a therapeu-
tic alternative for those at high risk of fracture. However, there is a high incidence 
of vertebral fractures after discontinuing medication (start only if there are no 
alternatives for further treatment) [2, 5, 6, 9–13, 15, 19, 27, 28].
In premenopausal women who do not need hormone replacement, bisphospho-
nates are the class of choice. Teriparatide is second line, as long as there is radiologi-
cal evidence of epiphyseal fusion of the long bones. Denosumab may also be an 
option in patients at high risk for fractures preferable [2, 5, 6, 9–13, 15, 19, 27, 28].
In addition to the new ACR guidelines, published in 2017, we also have the 
guidelines of the International Osteoporosis Foundation - European Calcified 





7.4.1 Effectiveness of pharmacological treatment
7.4.1.1 Bisphosphonates
Class responsible for increasing the half-life of osteoblasts. For a long time, it 
was believed that the protective effect of this class was due to its pro-apoptotic 
effect of osteoclasts. However, GC can inhibit this effect on osteoclasts, reducing 
drug efficacy [2, 9–13, 15, 27, 28].
Figure 3. 
Guidelines for the treatment of premenopausal women and men aged less than 50 from the joint international 
osteoporosis foundation (IOF) - European calcified tissue society (ECTS) glucocorticoid-induced osteoporosis 
(GIO) [9, 10].
Figure 4. 
Guidelines for the treatment of postmenopausal women and men aged 50 and over from the joint international 
osteoporosis foundation (IOF) - European calcified tissue society (ECTS) glucocorticoid-induced osteoporosis 
(GIO) [9, 10].
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For women and men who are candidates for pharmacological therapy, these 
are the first line of prevention and treatment of bone loss induced by glucocor-
ticoids. Especially alendronate and risendronate. A meta-analysis of 27 clinical 
trials showed a significant reduction in bone mass and structure improvement 
and a consequent reduction in fractures in the lumbar vertebrae and femoral 
neck. The reduction of non-vertebral fractures was not statistically significant 
[2, 9–13, 15, 27, 28].
There is not enough data to indicate the use of medications in pregnant women. 
Further studies are needed [2, 11–13, 15, 27, 28]. Below are the main representatives 
of the class:
Alendronate: Studies have shown an improvement in global bone density and 
a reduction in hip and femur fractures. There is no evidence of improvement in 
vertebra fractures. The protective effect was maintained for 2 years. Standard dose: 
5-10 mg, orally, daily or 35-70 mg, orally, weekly [2, 9–13, 15, 27, 28].
Risendronate: studies have shown a reduction in the incidence of lumbar verte-
bral and femoral neck fractures. Standard dose: 5 mg, orally, daily or 35 mg, orally, 
weekly [2, 9–13, 15, 27, 28].
Zoledronic acid (zoledronate): studies have shown a reduction in vertebral 
fractures, especially in high-risk patients. Standard dose: 5 mg, intravenous, 
annual. In the first three days after application, adverse effects such as arthralgia, 
fever, flu-like symptoms and, more rarely, hypocalcemia, which are more com-
mon in the first dose of this medication, may reduce the risk in subsequent doses 
[2, 9–13, 15, 27, 28].
Other bisphosphonates: pamidronate (oral and intravenous) can reduce the rate 
of bone loss induced by GC, but it has been replaced by zoledronic acid. Regarding 
ibandronate, studies for its routine use in GIO are lacking [11–13, 15, 27, 28].
7.4.1.2 Parathormone (PTH)
PTH stimulates bone formation as well as its resorption and its intermittent 
administration stimulates bone formation more than resorption [2, 9–13, 15, 27, 28]. 
In randomized studies, PTH showed a greater reduction in vertebral and femoral 
neck fractures than alendronate. The rate of non-vertebral fractures was similar 
with both medications [2, 11–13, 15, 27, 28].
Despite its great efficacy, it is not the first choice for treatment or prevention 
of osteoporosis induced by glucocorticoids, given its cost, subcutaneous admin-
istration and availability of other medications [2, 11–13, 15, 27, 28]. Indicated for 
treatment in postmenopausal women and men aged 50 or over in the following 
situations [2, 11–13, 15, 27, 28]:
• Severe osteoporosis (T-score less than or equal to −3.5 without fractures or 
previous episode of pathological fracture and T-score less than or equal to −2.5) 
before starting glucocorticoids.
• Osteoporosis (T-score less than −2.5) in patients who do not tolerate the use 
of bisphosphonates or who are contraindicated to oral bisphosphonates due to 
achalasia, esophageal scleroderma or esophageal stenosis, for example.
• Failure of other therapies: fracture with loss of bone density even with preven-
tion or treatment.
Teriparatide (exogenous PTH) is an option for women of childbearing age as 




fractures or accelerated bone loss (equal to or greater than 4% per year), while 
using glucocorticoids (minimum 7.5 mg per day of prednisone for 3 months or 
more) and there is no need for hormone replacement therapy. Its use is not recom-
mended for more than 2 years due to the potential risk of osteosarcoma. For patients 
who receive the medication, but remain at high risk for fractures, it is recom-
mended to start bisphosphonates soon after its completion. Standard dose: 20mcg 
per day, subcutaneous [2, 11–13, 15, 27, 28].
Abaloparatide (synthetic analogue of PTH-related protein), although prom-
ising, still does not have enough studies to indicate its routine use in GIO  
[11–13, 15, 27, 28].
7.4.1.3 Other pharmacological therapies
Denosumab: monoclonal antibody against RANKL, acts by inhibiting osteoclast 
formation and differentiation and re3ducing bone resorption, with a consequent 
increase in bone mineral density and reducing the risk of vertebral fracture. Used 
in postmenopausal women and men undergoing androgen deprivation treatment 
for prostate cancer. After discontinuation of use, the risk of vertebral fractures 
increases considerably. Analyze with the patient, treatment alternatives (usu-
ally bisphosphonates) after their removal to the segment. Standard dose: 60 mg, 
subcutaneous, every 6 months [2, 9–13, 15, 19, 27, 28].
Romosozumab: a potent anabolic anti-sclerostin antibody that could be consid-
ered as a substitute for PTH analogs. However, it lacks studies for its indication in 
GIO [4 18, 19, 21, 24, 25, 28].
Calcitonin: widely used in the past, but not very effective, it is currently  
not recommended for use because there are better treatment alternatives  
[2, 11–13, 15, 27, 28].
8. Monitoring
The guidelines guide the monitoring of BMD for the treatment segment. There 
is no consensus as to the frequency and period for measuring bone mineral density, 
but it is suggested that [2, 9–13, 15, 27, 28]:
• If density of bone mass stable or rising: every 6 months in the first year and 
every 1–2 years in subsequent years, this interval can be increased for every 
2–3 years;
• If bone mass density is decreasing or a new fracture is still being treated: 
investigate poor adherence to treatment, gastrointestinal absorption disorder, 
association of another disease with skeletal involvement, change to injectable 
medication in case of failure with oral treatment.
9. Conclusion
Glucocorticoids are medications widely used in continuous treatments in a 
significant portion of the world population. Given this, its continued use has 
considerable side effects, especially OIG. The guidelines for the treatment and 
prevention of this comorbidity are well established for postmenopausal women 
and men over 50 years of age. However, for patients below this range, studies are 
still lacking [2, 11–13, 15, 27, 28].
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